Precision Antibody to Develop Monoclonal Antibodies for NCI | GenomeWeb

NEW YORK (GenomeWeb News) – Precision Antibody said today that it will develop monoclonal antibodies for 20 cancer-related target proteins for a National Cancer Institute program, under an agreement with NCI contractor SAIC-Frederick.

The company will create the standardized, renewable antibodies for the NCI's Clinical Proteomic Technologies for Cancer (CPTC) project, which is focused on increasing the number of monoclonal antibody reagents that are available for clinical cancer proteomics research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.